FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers

Article Link: FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers

November 26, 2018 — The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).
This is the second…

Source: FDA New Drug Approvals